Drug Approval | June 13, 2025
FDA approves AbbVie’s mavyret as first and only treatment for acute hepatitis C
Now approved for both acute and chronic HCV in adults and children aged 3 and above
Now approved for both acute and chronic HCV in adults and children aged 3 and above
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries
Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body
Almost 300 million people globally have chronic hepatitis B
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
he product will be launched shortly in the US market.
Subscribe To Our Newsletter & Stay Updated
